Literature DB >> 2566219

Some aspects of the experimental induction and measurement of itch.

C F Wahlgren1, A Ekblom, O Hägermark.   

Abstract

Two different rating scales--a visual analogue scale (VAS) connected to a chart-recorder, and Pain-Track, a micro-computerized system with a 7-step-graded, fixed-point, non-verbal scale (FPNVS)--were evaluated for their capacity to assess experimental, histamine-induced itch continuously in 38 healthy subjects. The consequences for itch perception of using different injection sequences of various histamine concentrations were also investigated. A linear dose-response relationship was shown with random injection order for all subjective variables studied (itch latency and duration, maximal itch intensity, 'total itch index') with the VAS, but only for itch duration and 'total itch index' with the FPNVS. Using the VAS and injecting histamine solutions with increasing concentration, a significant dose-response curve was obtained for maximal itch intensity and 'total itch index', but when the same histamine stimuli were presented in the reverse (i.e. decreasing) order, there was no dose-response relationship. This indicates that central nervous system interaction may be unequally activated, depending on the order of different injected histamine stimuli. The objective variable flare was unaffected by the injection sequence. It is concluded that random injection order should be used in the assessment of itch sensation, in order to avoid systematic errors. The fact that the FPNVS did not discriminate as well as the VAS could indicate that our experimental stimuli were too weak to be properly discriminated with a 7-step-graded scale.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566219

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

1.  Quality of life in dermatomyositis.

Authors:  Renato Goreshi; Monika Chock; Kristen Foering; Rui Feng; Joyce Okawa; Matt Rose; David Fiorentino; Victoria Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-01       Impact factor: 11.527

2.  Epidural morphine vs hydromorphone in post-caesarean section patients.

Authors:  S H Halpern; R Arellano; R Preston; J Carstoniu; G O'Leary; S Roger; A Sandler
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

3.  [Documantation of pain-related data in outpatients with a specially designed pocket computer (Rating Box).].

Authors:  M Ostermeier; E Lang; M Pittel; C Forster
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

4.  Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.

Authors:  Kenya Kamimura; Takeshi Yokoo; Hiroteru Kamimura; Akira Sakamaki; Satoshi Abe; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Shuji Terai
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

5.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.

Authors:  Shuhei Yoshikawa; Takeharu Asano; Mina Morino; Keita Matsumoto; Hitomi Kashima; Yudai Koito; Takaya Miura; Yuko Takahashi; Rumiko Tsuboi; Takehiro Ishii; Haruka Otake; Junichi Fujiwara; Masanari Sekine; Takeshi Uehara; Kazuhito Yuhashi; Satohiro Matsumoto; Shinichi Asabe; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

6.  Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study.

Authors:  Pornanong Aramwit; Orathai Keongamaroon; Tippawan Siritientong; Nipaporn Bang; Ouppatham Supasyndh
Journal:  BMC Nephrol       Date:  2012-09-24       Impact factor: 2.388

7.  Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus.

Authors:  Hideki Kozono; Hiroshi Yoshitani; Ryoko Nakano
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.